Shop

PADCEV(Enfortumab Vedotinejfv) is known for the treatment of adult metastatic urothelial cancer patients who come under death receptor-1 (PD-1) or PD-L1 (programmed death-ligand 1) inhibitor, and
platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally
advanced or metastatic setting.

Uses:

• Bladder Cancer Treatment.
• urinary tract Cancer Treatment.

Side effects:

The most common adverse effects are:

• fatigue.
• Peripheral.
• Neuropathy.
• Decreased appetite.
• Rash.
• Alopecia.
• Nausea.
• Dysgeusia.
• Diarrhea.
• Dry eye.
• Pruritus.
• Dry skin.